These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 35371079)

  • 21. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
    Luo M; Lin Y; Liang R; Li Y; Ge L
    J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
    Chen J; Gao G; Zhang Y; Dai P; Huang Y
    BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.
    Sun L; Lin Y; Wang G; Zhang L; Hu L; Lu Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33439969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
    Wang B; Ran Z; Liu M; Ou Y
    Front Immunol; 2019; 10():1573. PubMed ID: 31379814
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
    Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.
    Li Z; Wang R; Qiu C; Cao C; Zhang J; Ge J; Shi Y
    Front Immunol; 2022; 13():834606. PubMed ID: 35392073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
    Song D; Wang Y; Zhu K; Tian L; Gao Q; Zhou J; Fan J; Wang X
    World J Surg Oncol; 2020 Jul; 18(1):176. PubMed ID: 32690026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMGB2 drives tumor progression and shapes the immunosuppressive microenvironment in hepatocellular carcinoma: insights from multi-omics analysis.
    Chen YZ; Meng ZS; Xiang ZL
    Front Immunol; 2024; 15():1415435. PubMed ID: 39247201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
    Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R
    Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
    Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
    Front Immunol; 2021; 12():653836. PubMed ID: 33897701
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
    Yin Z; Ma T; Chen S; Yu M
    Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
    Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
    Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The m
    Ma E; Li J; Shen C; Gu Y; Zhang X; Li L; Zhao J; Wang Z
    Front Immunol; 2023; 14():1227593. PubMed ID: 37691948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.
    Kula A; Dawidowicz M; Mielcarska S; Kiczmer P; Skiba H; Krygier M; Chrabańska M; Piecuch J; Szrot M; Robotycka J; Ochman B; Strzałkowska B; Czuba Z; Świętochowska E; Waniczek D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis.
    Gan W; Sun BY; Yang ZF; Ye C; Wang ZT; Zhou C; Sun GQ; Yi Y; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):325. PubMed ID: 38914802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy.
    Zhao H; Chen C; Yang C; Mo S; Zhao H; Tian Y
    Pathol Res Pract; 2022 Apr; 232():153808. PubMed ID: 35217267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.
    Jiayu F; Jiang Y; Zhou X; Zhou M; Pan J; Ke Y; Zhen J; Huang D; Jiang W
    Aging (Albany NY); 2022 Dec; 14(23):9550-9578. PubMed ID: 36462500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.